BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2933 related articles for article (PubMed ID: 14657064)

  • 21. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study.
    Bangalore S; Gong Y; Cooper-DeHoff RM; Pepine CJ; Messerli FH
    J Am Coll Cardiol; 2014 Aug; 64(8):784-93. PubMed ID: 25145522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).
    Winchester DE; Cooper-Dehoff RM; Gong Y; Handberg EM; Pepine CJ;
    Clin Cardiol; 2013 Aug; 36(8):442-7. PubMed ID: 23720247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
    Messerli FH; Mancia G; Conti CR; Hewkin AC; Kupfer S; Champion A; Kolloch R; Benetos A; Pepine CJ
    Ann Intern Med; 2006 Jun; 144(12):884-93. PubMed ID: 16785477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).
    Zineh I; Cooper-Dehoff RM; Wessel TR; Arant CB; Sleight P; Geiser EA; Pepine CJ
    Clin Cardiol; 2005 Jul; 28(7):321-8. PubMed ID: 16075824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
    Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group.
    Messerli F; Frishman WH; Elliott WJ
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):322-7. PubMed ID: 9544873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
    Elliott WJ; Hewkin AC; Kupfer S; Cooper-DeHoff R; Pepine CJ
    J Clin Hypertens (Greenwich); 2005 Nov; 7(11):654-63. PubMed ID: 16278523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
    Dasa O; Smith SM; Howard G; Cooper-DeHoff RM; Gong Y; Handberg E; Pepine CJ
    JAMA Netw Open; 2021 Apr; 4(4):e218418. PubMed ID: 33914047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
    Denardo SJ; Gong Y; Cooper-DeHoff RM; Farsang C; Keltai M; Szirmai L; Messerli FH; Bavry AA; Handberg EM; Mancia G; Pepine CJ
    PLoS One; 2015; 10(4):e0122726. PubMed ID: 25835002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity paradox in patients with hypertension and coronary artery disease.
    Uretsky S; Messerli FH; Bangalore S; Champion A; Cooper-Dehoff RM; Zhou Q; Pepine CJ
    Am J Med; 2007 Oct; 120(10):863-70. PubMed ID: 17904457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
    Kirchengast M
    J Hypertens Suppl; 1997 Mar; 15(2):S27-33. PubMed ID: 9218195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing microalbuminuria in type 2 diabetes.
    Ruggenenti P; Fassi A; Ilieva AP; Bruno S; Iliev IP; Brusegan V; Rubis N; Gherardi G; Arnoldi F; Ganeva M; Ene-Iordache B; Gaspari F; Perna A; Bossi A; Trevisan R; Dodesini AR; Remuzzi G;
    N Engl J Med; 2004 Nov; 351(19):1941-51. PubMed ID: 15516697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.
    Cooper-DeHoff RM; Gong Y; Handberg EM; Bavry AA; Denardo SJ; Bakris GL; Pepine CJ
    JAMA; 2010 Jul; 304(1):61-8. PubMed ID: 20606150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
    Vandell AG; Lobmeyer MT; Gawronski BE; Langaee TY; Gong Y; Gums JG; Beitelshees AL; Turner ST; Chapman AB; Cooper-DeHoff RM; Bailey KR; Boerwinkle E; Pepine CJ; Liggett SB; Johnson JA
    Hypertension; 2012 Oct; 60(4):957-64. PubMed ID: 22949529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil].
    Widimský J; Dzúrik R
    Vnitr Lek; 1998 Jun; 44(6):326-31. PubMed ID: 9820054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Gottdiener JS; Reda DJ; Massie BM; Materson BJ; Williams DW; Anderson RJ
    Circulation; 1997 Apr; 95(8):2007-14. PubMed ID: 9133508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
    Reynolds NA; Wagstaff AJ; Keam SJ
    Drugs; 2005; 65(13):1893-914. PubMed ID: 16114984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line drugs for hypertension.
    Wright JM; Musini VM; Gill R
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD001841. PubMed ID: 29667175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 147.